Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01576536 · ClinicalTrials.gov registry record

Genetic Variation in Platelet Aggregation

A clinical trial of Myocardial Infarction, sponsored by Vanderbilt University.

Completed
Registry status
117
Enrollment target
1
Study location

NCT01576536: Completed study of Myocardial Infarction, sponsored by Vanderbilt University.

NCT01576536 is a study of Myocardial Infarction that has completed, run by Vanderbilt University. The registered enrollment target is 117 participants, below the 4,680-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01576536, a study of Myocardial Infarction, has completed, sponsored by Vanderbilt University.

COMPLETED
Registry status
117 participants
Enrollment target
1
Study location

Study Summary

The aim of the study is to test whether genetic variation in the alpha 2A adrenergic receptor affects diurnal variation in platelet aggregation.

Primary Outcome

EC50 represents the epinephrine concentration that produced 50% of maximal platelet aggregation (representing sensitivity to epinephrine) EC50 values were not normally distributed and were log-transformed for analyses.

Conditions Studied

Study Locations (1)

Tennessee

  • the Vanderbilt University General Clinical Research Center - Nashville

Trial Details

FieldValue
Enrollment Target 117 participants
Start Date 2012-07
Est. Completion 2016-12
Vanderbilt University

430 total trials

What the finished NCT01576536 record still lists

NCT01576536 is an observational study that tracks outcomes without assigning an intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, below the 4,680-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Myocardial Infarction appearing as the primary indexed condition, and to 0 interventions.

NCT01576536 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT01576536 about?

NCT01576536 is a clinical study titled "Genetic Variation in Platelet Aggregation". The aim of the study is to test whether genetic variation in the alpha 2A adrenergic receptor affects diurnal variation in platelet aggregation.

What is the current status of trial NCT01576536?

This trial is currently completed. The enrollment target is 117 participants. The study started on 2012-07. Estimated completion is 2016-12.

What conditions does trial NCT01576536 study?

This clinical trial studies the following conditions: Myocardial Infarction.

Who is sponsoring clinical trial NCT01576536?

This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01576536 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myocardial Infarction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01576536's enrollment target sits among peer trials

117 49th of 64 higher than 16 of 64 other Myocardial Infarction trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Myocardial Infarction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03539822 · 117 participants · Phase 1

    Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

  • NCT03786692 · 117 participants · Phase 2

    Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

  • NCT04479696 · 117 participants · NA

    Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors

  • NCT04940585 · 117 participants · NA

    ROSE in Sunset Park

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01576536, the US trial registry maintained by the National Library of Medicine. NCT01576536 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.